Showing results (1-10 of 19) with videos related to
Sort By:
Pageof 2
Journal of Psychiatric Research|February 28, 2014
Depression symptom clusters and their predictive value for treatment outcomes: results from an individual patient data meta-analysis of duloxetine trialsAlexander Schacht, Philip Gorwood, Philip Boyce, et al.Cephalalgia : an International Journal of Headache|November 24, 2020
A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine preventionMessoud Ashina, David Doležil, Jo H Bonner, et al.International Journal of Clinical Pharmacology and Therapeutics|October 29, 2013
Prescribing patterns of duloxetine in France: a prescription assessment study in real-world conditionsBeatrice Augendre-Ferrante, Hernan Picard, David Evans, et al.Neuropsychologia|October 23, 2013
Reading impairment in schizophrenia: dysconnectivity within the visual systemFabien Vinckier, Laurent Cohen, Catherine Oppenheim, et al.Journal of Affective Disorders|August 4, 2012
Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized studyIrene Romera, Victor Pérez, Jose Manuel Menchón, et al.The Journal of Headache and Pain|August 5, 2020
Efficacy and safety of erenumab in women with a history of menstrual migraineJelena M Pavlovic, Koen Paemeleire, Hartmut Göbel, et al.Cephalalgia : an International Journal of Headache|April 16, 2019
Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled studyPeter J Goadsby, Koen Paemeleire, Gregor Broessner, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|October 27, 2022
Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trialUlrich Mrowietz, Jonathan Barker, Curdin Conrad, et al.American Journal of Clinical Dermatology|June 14, 2023
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet's SyndromePhilip J Mease, Gülen Hatemi, Maria Paris, et al.Headache|August 28, 2020
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% ResponseGregor Broessner, Uwe Reuter, Jo H Bonner, et al.Pageof 2